Document is current
Any future updates will be listed below
-
Authors
Renes, Joannes W.
Kupka, Ralph W.
Nolen, Willem A.
Have, Margreet ten
van der Markt, Afra
Boks, Marco P. M.
Regeer, Eline J.
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 7 February 2025
First Online: 15 February 2025
Declarations
:
: For all studies (SFBN-NFS, TBDN, EMBLEM, DBC, and Nemesis), participants gave informed consent. The TBDN, SFBN-NFS, and DBC studies were approved by the Medical Ethical Committee of the University Medical Center Utrecht, the Netherlands. Nemesis was approved by the Internal Review Board of the Trimbos Institute (Netherlands Institute of Mental Health and Addiction), The Netherlands. For the international EMBLEM study, local approval was obtained from an ethics committee, also in the Netherlands. Patients from the outpatient clinic participating in routine outcome measurement agreed in advance with the use of these anonymized data for research
: J.W. Renes and E.J. Regeer received speaker’s fees from AstraZeneca, Bristol-MyersSquibb, and Ely Lilly. M. ten Have, A. van der Markt, and M.P.M. Boks, report no potential conflicts of interest. W.A. Nolen has received grants from the Netherlands Organisation for Health Research and Development, the European Union; has received honoraria / speaker’s fees from Lundbeck and Aristo Pharma and has served as consultant for Daleco Pharma. R.W. Kupka received speaker’s fees for lectures on symposia sponsored by AstraZeneca, Bristol-Myers Squibb, Lundback, Sanofi, and Janssen.
